| Objective: To study the effects of activated carbon nanoparticles(ACNP)adsorbing MMC（ACNP-MMC） on the immune system and assess it’s applicationpotential in anti-tumor immune therapy.Method: Spleen cells of mice were isolated by aseptic method toprepare singlecell suspension.In vitro experiment, mouse spleen lymphocytes were exposed toMMC, ACNP and ACNP-MMC in final concentration of2.5,5,10,20,40,80μg/ml for48h.MTT assay and ELISA was respectively used to detect the proliferation and thesecretion of IL－2and IFN－γ induced by ConA in mouse spleen lymphocytes．Inorder to assess whether CBMC and MMC influnennce the immune system,H22livercancer mice model was used.CBMC and MMC were injected in mice inlow-dose(0.33mg/Kg), median-dose(1mg/kg) and high-dose(3mg/kg)respectitively.Macrophageic phagocytosis in mice was evaluated by utilizing the flow cytometryand detect the surface molecular markers of T lymphocyte by using flow cytometry.Results: The half inhibitory concentration (IC50) of MMC on mouse spleenlymphocytes was17.84μg/ml and that of ACNP-MMC was47.195μg/ml.Comparedwith normal control group, cell activity significantly decreased with rising of MMCconcentration. However, compared with MMC group, ACNP-MMC group was lessvenous for lymphocytes. ACNP can promote secretion of IFN－γ by mouse spleenlymphocytes. Compared with MMC group, the secretion of ACNP-MMC group wassignificantly increased(P＜0.01). ACNP has no influence on the secretion of IL-2bymouse spleen lymphocytes. It has no significantly difference between ACNP groupand ConA group(P＞0.05).However,Compared with MMC group, the secretion of CBMC group significantly increased(P＜0.01). In the H22mice liver cancermodel,the percentage of phagocytic cells among low-dose, median-dose, high-dosegroups of CBMC were (28.99±0.52)%,(33.73±0.71)%,(29.14±0.16)%as well asthe phagocytic index were(0.497±0.003),(0.577±0.018),(0.449±0.013) respectively.Both significantly increased compared to control group[(25.34±0.21)%,(0.419±0.003)](P＜0.05or P＜0.01).Compared with MMC group, the proportion ofCD4+/CD8+andCD3+/CD19+in the low-dose of CBMC showed no significantdifference(P＞0.05). However, the proportionality of CD4+/CD8+and CD3+/CD19+in the median-dose, high-dose groups of CBMC was higher than that in the MMCgroup(P＜0.01), ACNP group and tumor saline group showed no significantdifference(P＞0.05).Conclusion: CBMC can decrease the toxicity of MMC on mouse spleenlymphocytes and increase the secretion of IL－2and IFN－γ significantly.Promotes the phagocytosis of peritoneal macrophages, the activation level of immunecellular immunity effectively. CBMC has a higher potential at the aspect ofanti-tumor immune therapy. |
PDF Full Text Request